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Abstract
Background: Glycated haemoglobin (HbA1c), blood pressure and body mass index (BMI) are risk
factors for albuminuria, the latter in turn can lead to hyperlipidaemia. We used novel statistical
analyses to examine how albuminuria and chronic kidney disease (CKD) may influence the effects
of other risk factors on coronary heart disease (CHD).
Methods: A prospective cohort of 7067 Chinese type 2 diabetic patients without history of CHD
enrolled since 1995 were censored on July 30th, 2005. Cox proportional hazard regression with
restricted cubic spline was used to auto-select predictors. Hazard ratio plots were used to examine
the risk of CHD. Based on these plots, non-linear risk factors were categorised and the categorised
variables were refitted into various Cox models in a stepwise manner to confirm the findings.
Results: Age, male gender, duration of diabetes, spot urinary albumin: creatinine ratio, estimated
glomerular filtration rate, total cholesterol (TC), high density lipoprotein cholesterol (HDL-C) and
current smoking status were risk factors of CHD. Linear association between TC and CHD was
observed only in patients with albuminuria. Although in general, increased HDL-C was associated
with decreased risk of CHD, full-range HDL-C was associated with CHD in an A-shaped manner
with a zenith at 1.1 mmol/L. Albuminuria and CKD were the main contributors for the
paradoxically positive association between HDL-C and CHD for HDL-C values less than 1.1 mmol/
L.
Conclusion: In type 2 diabetes, albuminuria plays a linking role between conventional risk factors
and CHD. The onset of CKD changes risk associations between lipids and CHD.
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Coronary heart disease (CHD) is one of the leading causes
of premature death [1]. Patients with type 2 diabetes have
a 2–4 fold increased risk of CHD compared to those with-
out [2]. The United Kingdom Prospective Diabetes Study
(UKPDS) has identified hypertension, hyperglycaemia,
high low-density-lipoprotein cholesterol (LDL-C), low
high-density-lipoprotein cholesterol (HDL-C) and smok-
ing status as major risk factors of CHD [3].
Recent studies have confirmed that albuminuria is
another strong risk factor for cardiovascular disease [4-7].
This association holds true for albuminuria which occurs
early in life [8]. Glycated haemoglobin (HbA1c), blood
pressure (BP), HDL-C, smoking and body mass index
(BMI) are promoters of albuminuria [9]. The latter has
been shown to increase the likelihood of high TC and
LDL-C levels in a graded fashion [10]. While this relation-
ship may partly explain the increased risk of CHD in
patients with CKD [11], in patients with end-stage renal
disease (ESRD), most studies point to low HDL-C but not
high LDL-C as risk factors for cardiovascular diseases
(CVD) [12].
Although there is some evidence suggesting possible lin-
ear risk relationships between HbA1c, BP, LDL-C, HDL-C
and CHD [3], the linearity of these associations have
never been rigorously examined. In this study, we used a
non-linear approach to examine the possible impacts of
albuminuria and CKD on conventional risk factors and
new onset of CHD in a large prospective cohort of Chi-
nese Type 2 diabetic patients.
Methods
Subjects
The Prince of Wales Hospital is a regional hospital which
serves a population of 1.2 million in Hong Kong. The
Hong Kong Diabetes Registry was established in 1995 and
enrols 30–50 ambulatory diabetic patients each week. The
referral sources included general practitioners, commu-
nity and specialty clinics and patients discharged from
hospitals. Enrolled patients with hospital admissions
within 6–8 weeks prior to assessment accounted for less
than 10% of all referrals. The 4-hour assessment of com-
plications and risk factors was performed on an outpa-
tient basis, modified from the European DIABCARE
protocol [13]. Once a diabetic subject had undergone the
comprehensive assessment, he/she was considered to
have entered this study cohort and would be followed up
till death. The study was approved by the Clinical
Research Ethics Committee, Chinese University of Hong
Kong. The study complied with the Declaration of Hel-
sinki and written informed consent was obtained from all
patients.
Clinical endpoints including discharge diagnoses of hos-
pital admissions and mortality were censored on 30th July
2005. Details of hospital admissions were retrieved from
the Hong Kong Hospital Authority Central Computer Sys-
tem which records admissions to all public hospitals in
Hong Kong (accounting for 95% hospital beds in Hong
Kong). These databases were matched by a unique identi-
fication number, the Hong Kong Identity Card number,
which is compulsory for all residents in Hong Kong.
Hospital discharge summaries as coded by the Interna-
tional Classification of Diseases, Ninth Revision (ICD-9),
were used to identify first CHD. CHD was defined as (1)
nonfatal myocardial infarction (code 410), (2) nonfatal
ischemic heart disease (code 411–414) and (3) death due
to CHD (not including death due to heart failure). Fol-
low-up time was calculated as the period from enrolment
to the first CHD event, death or 30th July 2005, whichever
came first.
From 1995 to 2005, 7920 diabetic patients were enrolled
in the Registry. Among them, 332 with Type 1 diabetes
defined as acute presentation with diabetic ketoacidosis,
heavy ketonuria (>3+) or continuous requirement of insu-
lin within 1 year of diagnosis [14], and 5 with uncertain
type 1 diabetes status, were excluded from the analysis.
Forty-nine were excluded due to non-Chinese or
unknown nationality. Four hundred and sixty-seven
patients were further excluded for having a past history of
CHD (including heart failure) at enrolment. A total of
7067 Chinese type 2 diabetic patients without history of
CHD and heart failure at baseline were included in this
analysis.
Clinical measurements
Details of assessment methods, definitions and laboratory
assays have been previously described [15,16]. On the day
of assessment, patients attended the centre after at least 8
hours of fasting and underwent anthropometric measure-
ments and laboratory investigations. We used the Modifi-
cation of Diet in Renal Disease (MDRD) re-calibrated for
Chinese [17] to estimate GFR expressed in ml/min per
1.73 m2:
eGFR = 186 × [SCR × 0.011]-1.154 × [age]-0.203 × [0.742 if 
female] × 1.233
where SCR is serum creatinine expressed as μmol/l (origi-
nally in mg/dL, now converted to μmol/l) and 1.233 is the
coefficient for Chinese. Peripheral arterial disease (PAD)
was defined by the absence of foot pulses on palpation,
confirmed by Doppler ultrasound examination of the
ankle:brachial ratio <0.90 or treatment for PAD. Chronic
kidney disease was defined as eGFR <60 ml/min per 1.73
m2. Normoalbuminuria was defined as ACR <2.5 mg/Page 2 of 13
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albuminuria, between 2.5 mg/mmol (male) or 3.5 mg/
mmol (female) and 25 mg/mmol, macroalbuminuria,
≥25–150 mg/mmol. Due to its high risk nature, ACR ≥150
mg/mmol was considered as a separate group (see
results).
Statistical analyses
The Statistical Analysis System (SAS, Release 9.10) was
used to perform the statistical analysis (SAS Institute Inc.,
Cary, USA). In order to detect any thresholds, Restricted
Cubic Spline (RCS) with 4 knots (i.e. 1 term decomposed
into 3 terms: x, x1 and x2) [18] and Cox proportional haz-
ard regression with the stepwise algorithm (p < 0.05 for
entry and stay) were used to obtain a group of significant
predictors of CHD. The method on how to use RCS in Cox
proportionality has been described in detail by Harrell
[18]. The detailed algorithm on how to use a stepwise
algorithm in spline Cox regression models has been
described elsewhere [19].
Candidate variables at enrolment selected by the spline
Cox model included systolic/diastolic blood pressure
(BP), HbA1c, BMI, waist circumference, blood haemo-
globin (Hb), white blood cells (WBC) count, HDL-C,
LDL-C, triglyceride (TG), total cholesterol and drug usage
(Table 1). After several auto-selection cycles [19], spot
urine ACR and eGFR were also included in the final
model.
In exploratory analysis, we calculated hazard ratio (HR)
changes over full-ranges of baseline risk factors before and
Table 1: Baseline clinical and biochemical characteristics of 7067 Chinese Type 2 diabetic patients with no past history of coronary 
heart disease (CHD)
Development of CHD before the censoring date
No (n = 6716) Yes (n = 351)
median or % IQR median or % IQR P value
Follow-up time (years) 5.58 2.97–7.89 2.77 1.48–5.28 <0.001
Male 45.0% / 51.9% / 0.012†
Smoking status:
Current smoker 20.1% / 29.1% / 0.057†
Ex smoker 13.2% / 18.2% /
Age (years) 56 46–67 64 54–70 <0.001‡
Sex adjusted waist circumference (cm)* 55.9 0.16 61.9 0.72 <0.001‡
Body mass index (kg/m2) 24.7 22.4–27.3 24.6 22.7–26.7 0.748‡
Known duration of diabetes (year) 5 1–10 9 4–14 <0.001‡
Systolic blood pressure (mmHg) 134 121–148 141 130–155 <0.001‡
Diastolic blood pressure (mmHg) 76 69–83 78 70–85 <0.001‡
Peripheral arterial disease 5.4% / 13.7% / <0.001†
Retinopathy 25.6% / 42.5% / <0.001†
Sensory neuropathy 25.5% / 32.2% / 0.005†
Glycated haemoglobin (%) 7.3 6.4–8.6 7.6 6.6–9.3 <0.001‡
Blood haemoglobin (g/L) 13.8 12.8–14.9 13.6 12.4–14.7 0.019‡
Spot urinary ACR (mg/mmol) 1.88 0.75–9.81 7.65 1.61–72.3 <0.001‡
Increased albuminuria (ACR ≥3.5 mg/mmol in 
female & ≥2.5 mg/mmol.in male)
41.2% / 64.9% / <0.001‡
eGFR (ml/min/1.73 m2) 105.8 84.9–127.5 89.8 66.0–112.9 <0.001‡
eGFR <60 ml/min/1.73 m2 9.3% / 18.5% / <0.001
Low-density lipoprotein cholesterol (mmol/l) 3.10 2.50–3.80 3.52 2.9–4.2 <0.001‡
High-density lipoprotein cholesterol (mmol/l) 1.25 1.05–1.50 1.14 0.99–1.37 <0.001‡
Triglyceride (mmol/L) 1.37 0.96–2.06 1.55 1.11–2.18 <0.001‡
Total cholesterol (mmol/L) 5.20 4.50–5.90 5.54 4.85–6.30 <0.001†
Baseline use of drugs:
Oral anti-diabetic drugs 60.9% / 59.0% / 0.448†
Anti-hypertensive drugs 33.2% / 43.0% / <0.001†
Insulin 17.0% / 25.9% / <0.001†
Lipid lowering drugs 12.3% / 13.7% / 0.450†
ACEI or ARB 20.0% / 25.1% / 0.022†
IQR, inter-quartile range; eGFR, estimated glomerular filtration rate; ACEI, Angiotensin-converting enzyme inhibitors; ARB, angiotensin II receptor 
blockers; ACR, albumin:creatinie ratio; *, derived from analysis of covariance; †, derived from Chi-square text; ‡, derived from Wilcoxon two-
sample test.Page 3 of 13
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the impacts of albuminuria and CKD on these risk associ-
ations. Hazard ratio between two points of variable Xi can
be estimated by exp (y2 - y1), where y1 and y2 are the cor-
responding RCS function values of two Xi points. In this
study, the 25th or 75th percentile (for near linear relation-
ship) or zenith points (for non linear relationship) of
baseline variables were chosen as the reference point (y1)
to estimate HR of other points of baseline variable Xi (y2).
Here, y (y1 and y2) was the RCS function value of Xi, which
was calculated by the formula: the spline function value of
Xi = βx+βx1+βx2, where β, β1 and, β2 were estimated by
applying x, x1 and x2 as covariates in Cox models.
We then categorised significant continuous risk factors
identified in the HR plots and used Cox regression analy-
sis to confirm the findings in the risk curve analysis. Pro-
portionals hazards assumption and functional form were
checked using Supremum test [20], which is implemented
using ASSESS statement in the SAS procedure PROC
PHREG. A p-value of <0.05 for two-sided tests was consid-
ered to be statistically significant.
Results
Study population and predicting models
At enrolment, the median age of the cohort was 57 years
(interquartile range [IQR]: 46–67 years) with a median
disease duration of 5 (IQR: 1–11) years. During a median
follow-up period of 5.40 (IQR: 2.87–7.81) years, 351
(4.97%) patients developed incident CHD giving an inci-
dence rate of CHD of 9.28 (95% CI: 8.31–10.24) per 1000
person-years. During the follow-up period, 681 (9.64%)
patients died. Of these, 47 deaths were due to fatal CHD
(included in the 351 events, CHD as the principal diagno-
sis). Patients who developed CHD were older, had longer
duration of diabetes, more unfavourable lipid profile
(LDL-C, HDL-C and TG), worse renal function, higher
HbA1c, urinary ACR and WBC, lower Hb and were more
likely to be treated with insulin and antihypertensive
drugs at baseline that those who did not (Table 1).
The spline Cox model selected sex, smoking status (cur-
rent smoker/ex-smoker), use of angiotensin-converting
enzyme inhibitors (ACEI)/angiotensin II receptor block-
ers (ARB) and spline terms of age, duration of diabetes,
TC, HDL-C, blood Hb and insulin use at enrolment
(Model 1). Blood Hb (p = 0.1709) and insulin use (p =
0.1710) were no longer significant after further inclusion
of spline term of eGFR, while all other variables remained
significant. Further adjusting for spline term of ACR (p for
ACR = 0.0041) did not change the significance of other
variables in the model.
Risk factors of coronary heart disease
Estimated GFR was negatively associated with incident
CHD (Figure 1 and Table 2). The HR for CHD started to
rise at the trough value of 100 ml/min per 1.73 m2, and
rapidly from 60 ml/min per 1.73 m2 downwards. The HR
of ACR for CHD increased rapidly from 0 to 150 mg/
mmol before reaching a plateau. Similar trends with ACR
was observed in patients with normo, micro and mac-
roalbuminuria and those with ACR ≥150 mg/mmol (p <
0.05 for trend) (Figure 1 and Table 2).
There was near linear association between TC and CHD
risk, which was attenuated by adjustment for eGFR and
ACR (Figure 2a). Exclusion of patients with CKD led to a
higher HR for those with high TC >5.0 mmol/L. In
patients without CKD, the HR of TC for CHD started to
increase linearly from 5.0 mmol/L upwards. In patients
with CKD, the shape of the risk curve was changed to one
of "A-shaped" with a peak HR at 5.0 mmol/L (Figure 2b).
In patients with normoalbuminuria, there was no signifi-
cant association between TC and CHD (Figure 2c). Con-
versely, in patients with albuminuria, there was a linear
relationship between TC and CHD risk.
HDL-C was associated with CHD in an A-shaped manner
with a zenith at 1.1 mmol/L and a long tail on the right
(Figure 3a). Both HDL-C ≥1.40 mmol/L and HDL-C <0.80
mmol/L were associated with reduced risk of CHD (Table
3b), which remained significant after adjusting for eGFR
and ACR. The gradient of the HR curve accelerated more
rapidly from very low level of HDL-C up to 1.1 mmol/L in
the albuminuric group than in the non-albuminuric
group. After excluding patients with CKD (n = 690), the
negative risk association between CHD and HDL-C was
significant for HDL-C ≥1.40 mmol/L (p < 0.001) but not
for HDL-C level <0.80 mmol/L, p = 0.127).
Blood Hb was associated with CHD risk in a linear man-
ner (Figure 4). Excluding patients with CKD changed the
shape of the HR curve with a shoulder value at 12.5 g/dL.
Adjusting for eGFR also rendered the HR non significant
for Hb <12.5 g/dL versus. ≥12.5 g/dL (Table 2). Risk of
CHD increased with disease duration during the first 13
years, which then maintained at a high level (Figure 4 and
Table 2). Old age, male gender, current smokers, use of
ACEI/ARB and use of insulin were also associated with
higher risk of CHD (Figure 4 and Table 2).
Discussions
Our study re-affirms previous observations that age, male
gender, tobacco intake, long disease duration, high TC,
low HDL-C, high ACR, and low eGFR were independent
risk factors of CHD using conventional Cox regression
analysis. The novelty of our analysis lies in its ability to
demonstrate the powerful effects of albuminuria and CKDPage 4 of 13
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Full range risk associations between CHD and eGFR/ACRigure 1
Full range risk associations between CHD and eGFR/ACR. a. Black: adjusted for model 1 variables (p < 0.05); Blue: fur-
ther adjusted for ACR (p < 0.05). Model one variables include age, sex, and smoking status (current/ex), total cholesterol, 
HDL-C, Hb, eGFR and use of ACEI/ARB as well as use of insulin at enrolment. The hazard ratio was calculated using the 25th 
percentiles, 75th percentiles as the reference level. b. Black: adjusted for model 1 variables (p < 0.05); Blue: further adjusted for 
eGFR (p < 0.05).
Cardiovascular Diabetology 2007, 6:37 http://www.cardiab.com/content/6/1/37on modifying these risk relationships as evidenced by
changes in the HR plots of these risk factors. In particular,
the risk association between blood Hb and CHD was
entirely explained by eGFR and ACR while albuminuria
and CKD had profound effects on the CHD risk associa-
tion with HDL-C and TC.
Lipid parameters
The UKPDS reported graded increase in CHD risk with
LDL-C in type 2 diabetes [3]. In our model, instead of
LDL-C, TC was selected as a risk factor of CHD. More
detailed analysis revealed complex interplay between
lipid parameters, albuminuria, CKD and CHD risk in this
large prospective cohort of type 2 diabetic patients with a
broad range of renal function and albuminuria.
While we observed a near linear relationship between TC
and CHD, once ACR was fitted into the risk curve, this
relationship was present only in patients with albuminu-
ria. These findings concur with that from a large scale
cross-sectional study in USA (n = 17,702) which showed
risk association between albuminuria and hypercholeste-
rolemia (TC and LDL-C) in a graded fashion [10]. On the
other hand, the linear association between CHD and TC
at ≥5.0 mmol/L was mainly observed in patients without
CKD. Using the non-linear approach, we further demon-
strated that high HDL-C was associated with low CHD
risk when HDL-C was ≥1.1 mmol/L. However, for levels
lower than 1.1 mmol/L, the presence of albuminuria and,
in particular, CKD markedly changed the shape of the risk
curve to an 'A shaped' with a paradoxically positive asso-
ciation between CHD risk and HDL-C level, giving rise to
a zenith value of 1.10 mmol/L. These non-linear relation-
Table 2: Hazard ratios of significant baseline risk factors for coronary heart disease in type 2 diabetic patients (Model 1) before and 
after inclusion of eGFR and ACR into the model.
Model 1† Model 1 plus eGFR‡ Model 1 plus eGFR & ACR¶
Vaseline variables Hazard ratio (95% CI) p-value Hazard ratio (95% CI) p-value Hazard ratio (95% CI) p-value
Age (year):
<45 vs. 45–59 0.48 (0.28–0.81) 0.006 0.51 (0.30–0.86) 0.012 0.50 (0.29–0.84) 0.010
≥60 vs. 45–59 1.75 (1.31–2.33) <0.001 1.56 (1.16–2.09) 0.003 1.53 (1.14–2.06) 0.005
Female sex 0.64 (0.47–0.88) 0.006 0.66 (0.48–0.91) 0.010 0.69 (0.50–0.95) 0.023
Smoking status:
Ex-smoking vs. never 1.21 (0.84–1.76) 0.311 1.18 (0.81–1.71) 0.384 1.13 (0.78–1.64) 0.5202
Current vs. never 1.64 (1.15–2.33) 0.007 1.63 (1.15–2.33) 0.007 1.58 (1.11–2.26) 0.011
Duration of diabetes 
(year):
<5 vs. ≥13 0.43 (0.30–0.61) <0.001 0.45 (0.31–0.64) <0.001 0.49 (0.34–0.71) <0.001
5–12 vs. ≥13 0.71 (0.53–0.97) 0.028 0.74 (0.54–1.00) 0.048 0.78 (0.58–1.06) 0.118
Blood haemoglobin (g/
dL):
<12.5 vs. ≥12.5 g/dL 1.58 (1.16–2.15) 0.004 1.35 (0.98–1.87) 0.067 1.22 (0.88–1.69) 0.238
HDL-C (mmol/L):
<0.80 vs. 0.80–1.39 0.41 (0.18–0.93) 0.033 0.39 (0.17–0.88) 0.024 0.40 (0.18–0.90) 0.027
≥1.40 vs. 0.80–1.39 0.52 (0.38–0.70) <0.001 0.54 (0.39–0.73) <0.001 0.56 (0.41–0.76) <0.001
Total cholesterol 
(mmol/L)
1.22 (1.11–1.36) <0.001 1.20 (1.08–1.32) <0.001 1.12 (1.00–1.25) 0.045
Use of ACEI or ARB 1.72 (1.29–2.31) <0.001 1.59 (1.18–2.13) 0.002 1.44 (1.06–1.94) 0.018
Use of insulin 1.34 (0.99–1.81) 0.056 1.26 (0.93–1.70) 0.136 1.15 (0.85–1.56) 0.372
eGFR (ml/min per 1.73 
m2):
<60 vs. ≥90 / / 1.90 (1.27–2.84) 0.002 1.37 (0.89–2.10) 0.152
60–89.9 vs. ≥90 / / 1.51 (1.12–2.06) 0.008 1.36 (0.99–1.85) 0.055
Urinary ACR (mg/
mmol)ξ
Microalbuminuria / / / / 1.34 (0.97–1.85) 0.075
Macroalbuminuria / / / / 1.76 (1.19–2.58) 0.043
ACR ≥150 mg/mmol / / / / 2.64 (1.69–4.12) <0.001
eGFR, estimated glomerular filtration rate; ACR, albumin: creatinine ratio; HDL-C, high-density lipoprotein cholesterol; ACEI, Angiotensin-
converting enzyme inhibitors; ARB, angiotensin II receptor blockers ξ, Microalbuminuria is defined as ACR≥2.5 mg/mmol in male and ≥3.5 mg/mmol 
in female but <25 mg/mmol in both genders; macroalbuminuria here is defined as ≥25 mg/mmol but <150 mg/mmol in both genders. †, -2log 
likelihood without covariates = 4108.15 and with covariates = 3909.48; ‡, -2log likelihood with covariates = 3897.88; ¶, -2log likelihood with 
covariates = 3879.21.Page 6 of 13
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Full range risk associations between total cholesterol and CHD before and after adjustment for eGFR and ACRigure 2
Full range risk associations between total cholesterol and CHD before and after adjustment for eGFR and 
ACR. a. Black: derived from model 1 (p < 0.05); Blue: further adjusted for eGFR (p < 0.05); Red: further adjusted for eGFR and 
ACR (p < 0.05); Cyan: limited to eGFR ≥60 ml/min per 1.73 m2in model 1 (p < 0.05). Model one variables include age, sex, and 
smoking status (current/exit), total cholesterol, HDL-C, Hb, eGFR and use of ACEI/ARB as well as use of insulin at enrolment. 
b. Black: adjusted curve in patients with eGFR ≥60 ml/min per 1.73 m2 (p < 0.05); Blue: adjusted curve in patients with eGFR 
<60 ml/min per 1.73 m2 (p < 0.05). c. Black: adjusted curve in patients without albuminuria (p = 0.080); Blue: adjusted curve in 
patients with albuminuria (p < 0.05).
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Full range risk associations between HDL-C and CHD before and after adjustment for eGFR and ACRigure 3
Full range risk associations between HDL-C and CHD before and after adjustment for eGFR and ACR. a. Black: 
derived from model 1 (p < 0.05); Blue: further adjusted for eGFR (p < 0.05); Red: further adjusted for eGFR and ACR (p < 
0.05); Cyan: limited to eGFR ≥60 ml/min per 1.73 m2in model 1 (p < 0.05). Model one variables include age, sex, and smoking 
status (current/ex), total cholesterol, HDL-C, Hb, eGFR and use of ACEI/ARB as well as use of insulin at enrolment. The haz-
ard ratio was calculated using the zenith as the reference level. b. Black: adjusted curve in patients with eGFR ≥60 ml/min per 
1.73 m2 (p < 0.05); Blue: adjusted curve in patients with eGFR <60 ml/min per 1.73 m2 (p < 0.05). c. Black: adjusted curve in 
patients without albuminuria (p < 0.05); Blue: adjusted curve in patients with albuminuria (p < 0.05).
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Full range risk associations between CHD and Hb/duration of diabetes/age before and after adjustment for eGFR and ACRigure 4
Full range risk associations between CHD and Hb/duration of diabetes/age before and after adjustment for 
eGFR and ACR. a. Black: adjusted for model 1 variables (p < 0.05); Blue: further adjusted for eGFR (p: NS). Red: further 
adjusted for eGFR and ACR (p: NS); Cyan: limited to eGFR ≥60 ml/min per 1.73 m2 in model 1 (p < 0.05). Model one variables 
include age, sex, and smoking status (current/ex), total cholesterol, HDL-C, Hb, eGFR and use of ACEI/ARB as well as use of 
insulin at enrolment. The hazard ratio was calculated using the 25th percentiles, 75th percentiles as the reference level. b. Black: 
adjusted for model 1 variables (p < 0.05); Blue: further adjusted for eGFR (p < 0.05). Red: further adjusted for eGFR and ACR 
(p < 0.05); Cyan: limited to eGFR ≥60 ml/min per 1.73 m2in model 1 (p < 0.05). c. Black: adjusted for model 1 variables (p < 
0.05); Blue: further adjusted for eGFR (p < 0.05). Red: further adjusted for eGFR and ACR (p < 0.05); Cyan: limited to eGFR 
≥60 ml/min per 1.73 m2 in model 1 (p < 0.05)
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sion analysis. Using 0.80–1.39 mmol/L as the referent,
HDL-C <0.80 mmol/L and HDL-C ≥1.4 mmol/L were
both associated with reduced risk of CHD.
The nature of this positive association between HDL-C
and CHD for HDL-C values less than 1.1 mmol/L,
observed mainly in patients with CKD or albuminuria
requires further elucidation. However, in light of the
potent anti-inflammatory and anti-oxidant properties of
HDL-C particles [21,22], we postulate that these associa-
tions may be due to changes in the metabolic milieu asso-
ciated with CKD and severe albuminuria [23,24].
Against these thought-provoking findings, it is notewor-
thy that in the recent 4D study, treatment with atorvasta-
tin failed to reduce CHD risks in patients with ESRD [25].
These findings are not unexpected given the lack of asso-
ciation between LDL-C and CHD in patients with ESRD in
epidemiological studies as well as the non-association
between TC and CHD risk in our patients with CKD [12].
Furthermore, two recent clinical trials failed to confirm
the hypothesis that increasing HDL-C can reduce the pro-
gression of coronary atherosclerosis [26,27]. Again, our
findings regarding the powerful effects of albuminuria
and CKD on altering the pattern of risk association
between HDL-C and CHD highlight the complexity of
interrelationships between energy metabolism and organ
function.
Blood haemoglobin, renal impairment and albuminuria
Our group and others have reported the risk association of
CHD with low eGFR [11,28]. In our current analysis,
adjustment for ACR greatly attenuated the association
between eGFR and CHD risk, suggesting that the risk asso-
ciation was in part mediated by albuminuria, a marker of
endothelial dysfunction. In this cohort, we detected a
sharp and linear association between CHD risk and ACR
starting from 0 to 150 mg/mmol. This observation there-
fore concord with findings by Gerstein et al showing that
any degree of albuminuria is a risk factor for cardiovascu-
lar disease [29].
There is strong evidence showing that low blood Hb is a
strong predictor for CHD [30,31]. In our analysis, the risk
association between CHD risk and blood Hb was ren-
dered non significant after adjustment for eGFR and
exclusion of patients with CKD. These findings suggest
that blood Hb may merely serve as a surrogate marker for
CKD and thus may explain the negative results of two
recent clinical trials which failed to confirm the beneficial
effects of correction of anaemia using erythropoietin ther-
apy on cardiovascular endpoints in patients with ESRD
[32,33].
Other CHD risk factors
In patients with diabetes less than 13 years, there was lin-
ear relationship between CHD risk and disease duration.
In patients with disease more than 13 years, the statistical
significance of disease duration disappeared. This may be
confounded by the strong relationship between disease
duration and albuminuria and that between albuminuria
and hypercholesterolaemia [9,10].
Age is a well-known risk factor of CHD [3]. However, our
study suggests that this age-associated CHD risk was in
part mediated by loss of renal function after the age of 55
years. In agreement with the UKPDS [3], we also found a
risk-protecting effect of female gender on CHD. Smoking
is a well-known risk factor of CHD which is also inde-
pendently associated with CHD in our cohort [3].
Although there is strong epidemiological evidence sup-
porting the risk association between CHD and glycemic
control [3,34], the UKPDS failed to confirm the benefits
of improving glycemia on CHD rates in an interventional
setting [35]. In our cohort, HbA1c was a significant predic-
tor for CHD with a HR of 1.07 for every 1% increase in
HbA1c (p = 0.0136) after controlling for age, sex, SBP and
smoking status. However, this significance was rendered
non significant once ACR, TC, HDL-C, or disease duration
were adjusted for. Other studies have shown that
improvement in glycemic control reduced albuminuria
and hypercholesterolaemia [35-37]. Taken together, with
the possible causal effect of albuminuria on hypercholes-
terolaemia [10], our findings suggest that the effect of
HbA1c on CHD risk is likely to be mediated through risk
factors such as albuminuria and lipids.
Blood pressure is a strong risk factor for CHD in type 2
diabetes [3]. In our analysis, the age and sex adjusted haz-
ard ratio of SBP for CHD was 1.23 (95% CI: 1.07–1.18)
per 10 mmHg (p < 0.001). However, after adjusting for
the spline term of ACR, the significance of SBP did not
persist (p = 0.172). Removal of the use of ACEI/ARB in the
spline Cox model (without ACR and eGFR), the spline
term of SBP was significant (p = 0.007). These findings
suggest that low BP and use of ACEI/ARB were associated
with reduced risk of CHD, largely mediated by albuminu-
ria.
Similar to the findings from the UKPDS [3], BMI and
waist circumference were not selected as risk factors of
CHD in the model. The age and sex adjusted HRs were
also not significant (p = 0.494 for BMI and 0.182 for waist
circumference). Although BMI has been implicated in
albuminuria [9], the association between BMI and CHD
may be confounded by other mediators such as dyslipi-
demia and inflammation. Besides, the prognostic signifi-Page 10 of 13
(page number not for citation purposes)
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diabetes may become paradoxically reversed [38].
Limitations
This prospective cohort consists of a heterogeneous
cohort of type 2 diabetic patients with a wide range of dis-
ease duration and risk factors. Although this heterogeneity
and the use of single baseline values may theoretically
reduce the precision of these risk estimations, this draw
back was partly compensated by the relatively large
number of clinical events, detailed phenotyping at base-
line and long period of observation. Overall, results gen-
erated from both conventional and non-linear
approaches are robust and consistent which have gener-
ated alternative hypotheses which are biologically plausi-
ble. Further clinical and experimental studies are required
to confirm these findings.
Conclusions and Implications
Using a large prospective database and relatively novel
and robust statistical methods, we have found a strong
linear association between TC and CHD only in patients
with albuminuria. Adjusting for eGFR and albuminuria
attenuated the associations between lipid, Hb, BP, dura-
tion of diabetes and CHD, suggesting that albuminuria
plays a linking role between these risk factors and CHD.
The onset of CKD further changes risk associations
between lipids (such as TC and HDL-C) and CHD.
Recently, several major randomised clinical trials have
yielded negative results regarding the effects of correcting
anemia and reducing LDL-C on cardiovascular outcomes
in patients with ESRD as well as that of raising HDL-C on
reducing progression of atherosclerosis.
Based on these observations, we infer the following path-
ways to CHD in type 2 diabetes: 1). Hyperglycaemia and
hypertension lead to albuminuria, a marker of endothe-
lial and renal damage; 2). Albuminuria leads to hyperlip-
idaemia which further increases the risk of CHD; and 3).
Albuminuria, both as a surrogate for multiple risk factors
and causal factors, leads to deterioration of renal function
and 5). Reduced renal function further changes the pat-
tern of risk association between HDL-C and CHD, i.e., the
predictive value of very low HDL-C (<0.8 mmol/L) no
longer holds when CKD has developed.
Understanding the complex relationships among risk fac-
tors of CHD in type 2 diabetes is an important step
towards further reducing CHD risk in type 2 diabetes. For
example, reducing albuminuria might further control
hyperlipidaemia and enhance the benefits of controlling
traditional risk factors such HbA1c, BP and LDL-C. Our
data also suggest that retarding rate of deterioration of
renal function and correcting anaemia may have impor-
tant cardioprotective effects. However, these hypotheses
will need to be confirmed by both experimental and inter-
ventional studies.
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